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Objectives
Chronic hepatitis C virus (HCV) and HIV viral infections are characterized by systemic
inflammation. Yet the relative levels, drivers and correlates of inflammation in these settings are
not well defined.
Methods
Seventy-nine HIV-infected patients who had been receiving antiretroviral therapy (ART) for more
than 2 years and who had suppressed plasma HIV levels (< 50 HIV-1 RNA copies/mL) were
included in the study. Two patient groups, HCV-positive/HIV-positive and HCV-negative/
HIV-positive, and a control group comprised of healthy volunteers (n = 20) were examined.
Markers of systemic inflammation [interleukin (IL)-6, interferon gamma-induced protein (IP)-10,
soluble tumour necrosis factor receptor-I (sTNF-RI) and sTNF-RII], monocyte/macrophage
activation [soluble CD163 (sCD163), soluble CD14 and neopterin], intestinal epithelial barrier loss
[intestinal fatty acid binding protein (I-FABP) and lipopolysaccharide (LPS)] and coagulation
(D-dimers) were analysed. CD4 na€ıve T cells and CD4 recent thymic emigrants (RTEs) were
enumerated.
Results
Plasma levels of IP-10, neopterin and sCD163 were higher in HCV/HIV coinfection than in HIV
monoinfection and were positively correlated with indices of hepatic damage [aspartate
aminotransferase (AST), alanine aminotransferase (ALT) and the AST to platelet ratio index (APRI)].
Levels of I-FABP were comparably increased in HIV monoinfection and HIV/HCV coinfection but
LPS concentrations were highest in HCV/HIV coinfection, suggesting impaired hepatic clearance of
LPS. Plasma HCV levels were not related to any inflammatory indices except sCD163. In coinfected
subjects, a previously recognized relationship of CD4 na€ıve T-cell and RTE counts to hepatocellular
injury was defined more mechanistically by an inverse relationship to sCD163.
Conclusions
Hepatocellular injury in HCV/HIV coinfection is linked to elevated levels of certain inflammatory
cytokines and an apparent failure to clear systemically translocated microbial products. A related
decrease in CD4 na€ıve T cells and RTEs also merits further exploration.
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Introduction
An estimated 10–15% of the 35 million people living
with HIV infection world-wide are also infected with
hepatitis C virus (HCV) [1]. These two viral diseases
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can adversely influence each other. HIV speeds up the
course of HCV infection, accelerating liver fibrosis and
cirrhosis, and promoting liver cancer [2,3]. In turn,
HCV coinfection has been linked to CD4 and CD8
T-cell activation [4,5] and increased CD4 T-cell apopto-
sis [6,7], and in some studies has been associated with
diminished CD4 T-lymphocyte restoration with
antiretroviral therapy (ART) [8].
Indices of systemic inflammation and coagulation are
now recognized as important predictors of morbidity
and mortality in treated HIV infection [9–11]. Here, we
investigated whether HIV-infected patients with sup-
pressed viraemia on combination ART have different
systemic levels of inflammation or coagulation from
HCV-coinfected patients and, if so, whether these levels
are related to indices of hepatic damage.
Patients and methods
This work was approved by the Institutional Review
Board of Perm Regional Center for Protection against
AIDS and Infectious Diseases (IRB00008964). All patients
provided their written informed consent.
Seventy-nine HIV-infected patients receiving ART for
more than 2 years and 20 healthy controls participated
in the study. All patients had a confirmed diagnosis of
HIV infection, were adherent to their ART regimen, and
had plasma HIV RNA levels < 50 HIV-1 RNA copies/
mL. ART regimens included two nucleoside reverse
transcriptase inhibitors (NRTIs) together with a riton-
avir-boosted protease inhibitor or a nonnucleoside
reverse transcriptase inhibitor. HCV coinfection was
confirmed by the demonstration of HCV RNA in plasma
using a polymerase chain reaction (PCR)-based assay
(Quantitative RT-Gepatogen C kit; DNA Technology,
Moscow, Russia); HCV-uninfected subjects each had a
negative test for serum antibodies to HCV. Patients
who had been exposed to interferon/ribavirin treatment
were excluded from the study. HIV infection duration
was timed from the date of the first positive western
blot analysis. HCV infection duration was calculated
from when the first positive enzyme-linked immunosor-
bent assay (ELISA) result was received. A report
describing the lymphocyte phenotype in these subjects
has been published previously [12].
Three groups were included in the study: (1) HIV/HCV-
coinfected patients (n = 42); (2) HIV-monoinfected
patients (n = 37); (3) uninfected volunteers (n = 20).
There were no differences between the two infected
groups in nadir CD4 T-cell count (Table 1) or prior AIDS-
defining conditions. No information on alcohol consump-
tion and smoking was provided.
HIV and HCV levels in plasma
Plasma levels of HIV RNA were assessed using a Versant
440 amplifier (Siemens, Washington, D.C, USA) and
Versant HIV 1 RNA 3.0 assay b kits (Bayer, Leverkusen,
Germany). HCV RNA levels in plasma were measured
using an iCycler IQ5 (Bio-Rad, Hercules, CA, USA) and
real-time PCR Quantitative RT-Gepatogen C kits (DNA
Technology).
Blood samples for T-cell phenotyping
Approximately 30 mL of blood was collected from each
participant in Vacutainer tubes containing Ethylenediami-
netetraacetic acid (EDTA) (Becton Dickinson, Franklin
Lakes, NJ, USA). CD4 T-cell numbers were counted in real
time using the IMK-Lymphocyte Kit (Becton, Dickinson
and Company, San Jose, CA, USA) and a BD FACSCalibur
flow cytometer. (Franklin Lakes, NJ, USA) Peripheral
blood mononuclear cells (PBMCs) were isolated using
Diacoll-1077 (Dia-M, Moscow, Russia) density sedimenta-
tion. PBMCs were cryopreserved in fetal calf serum and
dimethyl sulfoxide, and then stored at 196°C.
Monoclonal antibodies
Fluorochrome-tagged monoclonal antibodies (anti-CD3-
PerCP, anti-CD4-AF700, anti-CD27-APC-Cy7, anti-
CD45RA-APC, anti-CCR7-PE-Cy7 and anti-CD31-FITC)
and isotype control antibodies were obtained from Becton
Dickinson. A Live/Dead Fixable Yellow Dead Cell Stain
Kit was obtained from Life Technologies (Grand Island,
NY, USA).
Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were thawed
and stained and viable cells were enumerated using a
Becton Dickinson LSR II Flow Cytometer. Na€ıve CD4 T
cells were identified as CD3+CD4+CD27+CD45RA+CCR7+.
Na€ıve CD31+ T lymphocytes were considered to be recent
thymic emigrants (RTEs). At least 100 000 events in the
lymphocyte gate were collected for each sample. Relative
values were determined from the cytometer data. Abso-
lute lymphocyte subpopulations were calculated based on
CD4 T-cell numbers detected in fresh blood.
ELISA
ELISA kits for the detection of interleukin-6 (IL-6), inter-
feron gamma-induced protein-10 (IP-10), soluble CD163
(sCD163), soluble CD14 (sCD14), soluble tumour necrosis
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factor receptor-I (sTNF-RI), soluble tumour necrosis factor
receptor-II (sTNF-RII) and intestinal fatty acid binding
protein (I-FABP) were purchased from R&D Systems
(Minneapolis, MN, USA). D-dimer kits were purchased from
Diagnostica Stago (Asnieres, France). Neopterin competi-
tive ELISA kits were purchased from IBL International
(Hamburg, Germany). Lipopolysaccharide (LPS) levels were
assessed using a Hycult Biotech Limulus amebocyte lysate
chromogenic endpoint assay kit (Uden, the Netherlands).
Assays were performed according to the kit instructions.
Plasma samples were diluted as needed to assure that
results were within the linear range of the assay.
Statistical analysis
Data are reported as medians and interquartile ranges.
Groups were compared using the Mann–Whitney test.
Multiple regression analysis was used to control for the
effects of possible confounding factors. Correlation analysis
was performed using the Spearman method. All statistical
analyses were performed using STATISTICA 6.0 software (Dell
Software, Round Rock, TX, USA).
Results
Clinical characteristics
The ages of the HIV-infected patient groups and
healthy controls were comparable (Table 1). The median
age was 33 years in the HIV/HCV-coinfected group,
34 years in the HIV-monoinfected group and 31 years
in the uninfected group. Men were overrepresented
(61.9%) among HIV/HCV-coinfected patients, reflective
of the features of the HCV infection epidemic in Russia
[13]. In contrast, the HIV-monoinfected patients in
this study were predominantly (78.4%) women. The
difference in the gender ratio was significant
(P < 0.001). In the healthy control group, 40% were
Table 1 Clinical characteristics of HIV/hepatitis C virus (HCV)-coinfected and HIV-monoinfected patients
Characteristic HIV/HCV coinfected HIV monoinfected Uninfected
Examined subjects (n) 42 37 20
Age (years) [median (IQR)]* 33 (32–37) 34 (31–41) 31 (26–35)
Male gender [n (%)] 26 (61.9) 8 (21.6) 8 (40.0)
HIV transmission route [n (%)]
Injecting drug use 36 (85.7) 1 (2.7) –
Sexual 6 (14.3) 36 (97.3) –
Homosexuals 0 0 0
Sex workers 0 0 0
Active drug users 0 0 0
HIV infection characteristics
Infection duration (years) [median (IQR)] 11 (9–12)
P1–2 < 0.001
8 (6–10) –
HAART duration (years) [median (IQR)] 3.5 (2–5)
P1–2 > 0.05
4 (3–5) –
Nadir CD4 count (cells/lL) [median (IQR)] 140 (100–170)
P1–2 > 0.05
150 (106–170) –
CD4 count at study entry (cells/lL) [median (IQR)] 350 (260–450)
P1–2 > 0.05
410 (290–570)
P2–3 < 0.001
1050 (660–1280)
P1–3 < 0.001
HIV viral load (copies/mL) [median (IQR)] < 50 < 50 –
HCV infection characteristics
Infection duration (years) [median (IQR)] 11 (8–12) – –
HCV viral load (log10 copies/mL) [median (IQR)] 6.21 (2.88–6.59) < 2.88 < 2.88
AST (U/L) [median (IQR)] 47 (29–75)
P1–2 < 0.001
19 (17–23)
P2–3 > 0.05
19 (15–24)
P1–3 < 0.001
ALT (U/L) [median (IQR)] 59 (28–112)
P1–2 < 0.001
18 (14–23)
P2–3 > 0.05
19 (15–26)
P1–3 < 0.001
c-GT (U/L) [median (IQR)] 71 (35–122)
P1–2 < 0.001
30 (23–45)
P2–3 > 0.05
27 (21–34)
P1–3 < 0.001
Albumin (g/L) [median (IQR)] 41.7 (40.9–42.5)
P1–2 > 0.05
41.3 (40.4–43.5)
P2–3 > 0.05
41.8 (40.8–42.6)
P1–3 > 0.05
Platelets (109/L) [median (IQR)] 202 (167–244)
P1–2 > 0.05
234 (177–276) –
APRI [median (IQR)] 0.6 (0.4–1.2)
P1–2 < 0.001
0.2 (0.2–0.3) –
AST, aspartate aminotransferase; ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; HAART, highly active antiretroviral therapy; IQR,
interquartile range; c-GT, c-glutamyl transpeptidase.
*Median with interquartile range (25th–75th percentile).
Statistical analyses were carried out using the Mann–Whitney test.
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men. The known duration of infection was longer in
coinfected subjects than in HIV-monoinfected subjects
(11 vs. 8 years, respectively). There were no differences
between the two infected groups in CD4 T-cell numbers
before or after ART initiation. In HIV/HCV-coinfected
subjects, the median HCV RNA levels exceeded
1 000 000 copies/mL and liver enzymes were elevated
compared with the levels in HIV-monoinfected patients,
while albumin levels and platelet counts in coinfected
and monoinfected persons were not significantly differ-
ent. The AST to platelet ratio index (APRI) for predict-
ing fibrosis and cirrhosis [14] was higher in the HIV/
HCV-coinfected group than in the HIV-monoinfected
group.
Systemic inflammation indices are elevated in HCV/
HIV coinfection
Plasma levels of the inflammatory cytokines IL-6 and
IP-10, the monocyte/macrophage markers neopterin
and sCD163, and sTNF-RII were higher in HIV/HCV-
coinfected patients than in patients who were HIV-
monoinfected and, except for sTNF-RII, were also
higher than in healthy controls (Fig. 1). As the two
infected groups differed in the duration of HIV infec-
tion and gender composition, we investigated whether
these factors might have confounded our results. After
adjustment for these factors, the difference between the
two HIV-positive groups in the levels of IL-6 and
sTNF-RII lost statistical significance. With correction for
gender and duration of HIV infection, levels of IP-10,
sCD163 and neopterin remained significantly higher in
HCV/HIV-coinfected subjects than in HIV monoinfec-
tion. Median levels of IP-10, sCD163 and sTNF-RII in
HIV-monoinfected subjects were not different from
those in healthy controls, but IL-6, neopterin and
sCD14 levels were higher in HIV-monoinfected patients
than in healthy subjects. These differences in inflamma-
tory markers may be associated with intestinal epithe-
lium damage, as plasma I-FABP levels in both groups
Fig. 1 Plasma indicators of systemic inflammation in hepatitis C virus (HCV)/HIV-coinfected patients. Plasma concentrations of interleukin (IL)-
6, interferon gamma-induced protein (IP)-10, soluble CD163 (sCD163), neopterin, soluble tumour necrosis factor receptor-II (sTNF-RII) and sol-
uble CD14 (sCD14) are shown in three patient groups: patients coinfected with HCV/HIV, HIV-monoinfected patients and healthy volunteers
without HIV or HCV infection. Columns with horizontal lines show medians with interquartile ranges. *P < 0.05; **P < 0.01; ***P < 0.001
(Mann–Whitney test).
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of HIV-infected patients were also significantly higher
(P < 0.01) than those in the control group, and plasma
LPS concentrations were higher in HCV/HIV-coinfected
subjects than in HIV-monoinfected patients and
uninfected controls (Fig. 2). In contrast, plasma D-dimer
levels, reflecting coagulation and fibrinolysis, were
similar among the three groups.
To explore the possibility that HCV coinfection
increases monocyte/macrophage activation (sCD163 and
neopterin levels) and stimulates interferon (IFN)-depen-
dent production of the chemokine IP-10, we assessed the
relationship of these markers to indices of HCV replica-
tion and hepatic injury.
In the group of HCV/HIV-coinfected patients, we found
highly significant and consistent correlations between
indices of hepatic damage [AST, ALT and APRI] and
plasma IP-10, sCD163 and neopterin (Fig. 3). Correlations
with levels of sCD14, I-FABP, sTNF-RI and sTNF-RII were
not significant. AST levels correlated with levels of D-
dimers, albeit weakly (R = 0.326; P < 0.05). HCV levels
in plasma were also associated with liver enzyme eleva-
tions [RAST–HCV = 0.527 (P < 0.001), RALT–HCV = 0.483
(P < 0.01) and RAPRI–HCV = 0.361 (P < 0.05)], but, among
all the markers of systemic inflammation, correlated only
with sCD163 concentration (RsCD163–HCV = 0.316;
P < 0.05).
In an earlier report in this cohort, we found inverse
significant relationships between the magnitude of hep-
atic damage (ALT, AST and APRI) and absolute numbers
of circulating CD4 RTEs [12]. Having found that indices
of hepatocellular injury are linked to inflammatory
markers in HIV/HCV coinfection, we examined here the
relationship between these inflammatory markers and
CD4 RTEs, and found that higher levels of sCD163 were
associated with fewer circulating CD4 RTEs and with
fewer CD4 na€ıve T cells (Fig. 4).
Discussion
HIV and HCV infections are each characterized by
increases of various inflammatory marker levels in the
blood [15–17]. With suppressive ART, plasma concen-
trations of inflammatory markers tend to decrease but
do not always normalize [18]. Here, we compared
plasma levels of inflammatory and coagulation markers
in HIV-infected and HIV/HCV-coinfected patients who
were receiving suppressive ART. In both groups, HIV
levels in plasma were suppressed while HCV replication
was uncontrolled, providing an opportunity to explore
the effects of HCV replication in the setting of chronic
HIV infection while attenuating the direct effects of
HIV replication. Plasma concentrations of IL-6, IP-10,
sCD163, neopterin and sTNF-RII were significantly
higher in coinfected subjects than in HIV-infected
patients not infected with HCV. As the patient groups
were not comparable in gender composition and known
duration of HIV infection, adjustment for these two
factors left only differences in IP-10, sCD163 and
neopterin remaining significantly and independently
higher in HCV/HIV-coinfected patients than among
HIV-infected subjects not infected with HCV. Although
a contribution of ART-induced hepatotoxicity in the
setting of HCV/HIV coinfection cannot be excluded, a
simpler and more plausible explanation is that the
observed effects are related to HCV/HIV-mediated liver
damage [19,20].
Fig. 2 Plasma concentrations of intestinal fatty acid binding protein (I-FABP), lipopolysaccharide (LPS) and D-dimers in hepatitis C virus
(HCV)/HIV-coinfected and HIV-monoinfected patients. Three patient groups are shown: HCV/HIV-coinfected patients, HIV-monoinfected patients
and healthy uninfected volunteers. Medians, interquartile ranges, and upper and lower ranges are presented. **P < 0.01; ***P < 0.001
(Mann–Whitney test).
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Whereas there are numerous sources of IP-10, in HCV
infection, IP-10 is synthesized by liver sinusoidal lining
cells [21] and is induced by interferons and co-stimulated
by TNF-a and IL-1 [22,23]. The primary role of the che-
mokine IP-10 is to recruit CD4 Type 1 helper T cells
(Th1), CD8 cytotoxic T cells, and natural killer (NK) cells
through interaction with Chemokine (C-X-C motif) recep-
tor 3 (CXCR3) to provide a proinflammatory antiviral
immune response [24–27].
During chronic HCV infection, an increase in the num-
ber of macrophage-like Kupffer cells is observed [28,29].
These cells acquire an activation phenotype [30], and
express greater levels of CD33 and CD163 [31,32]. Blood
levels of sCD163 may reflect systemic macrophage
activation. Higher levels of sCD163 are seen in subjects
with HCV/HIV coinfection than in HIV-monoinfected
patients [33] and in HCV infection are linked to the
development of cirrhosis [34].
While effective ART does not reliably result in com-
plete suppression of immune activation and inflammatory
responses in HIV-infected patients [35,36], we found here
that plasma levels of IL-6, neopterin and sCD14 in sub-
jects not coinfected with HCV remained higher than in
controls, while levels of IP-10, sCD163 and TNF-RII were
similar to control levels. The drivers of persistent inflam-
mation in treated HIV infection and HIV/HCV coinfection
are not entirely clear but, in these settings, damage to the
gut epithelial barrier has been implicated in promoting
Fig. 3 Relationship between hepatocellular damage and indices of systemic inflammation. The correlation analysis was performed using the
Spearman method. ALT, alanine aminotransferase; AST, aspartate aminotransferase; APRI, AST to platelet ratio index; IP-10, interferon gamma-
induced protein-10.
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translocation of microbial products from the gut lumen
into the systemic circulation [37]. Elevated plasma levels
of I-FABP are regarded as a marker of this intestinal
damage [19,38]. Interestingly, we found increased plasma
levels of LPS in HIV infection and even higher levels in
HIV/HCV coinfection, while in HIV monoinfection and
HIV/HCV coinfection the elevated levels of I-FABP and
the LPS co-receptor sCD14 were comparable. These data
suggest that in HIV-infected/HCV-uninfected and HIV/
HCV-coinfected individuals the gut barrier defect may be
comparable, allowing bacterial products access to the
portal vein. However, impaired hepatic clearance of LPS
in HCV coinfection may result in even higher levels of
LPS in the peripheral blood of HIV/HCV-coinfected
patients compared with HIV-infected patients not infected
with HCV. It is also possible that the impaired clearance
of LPS and other microbial products not measured here
may contribute to the marked increases in other inflam-
matory mediators that we found in HCV/HIV coinfection
compared with levels in HIV-infected patients negative
for HCV.
While sCD14 levels were elevated in both HIV infection
and HCV/HIV coinfection, there was no significant differ-
ence in sCD14 levels between HIV monoinfection and
HIV/HCV coinfection. In contrast, Sandler et al. [19]
found that sCD14 level was correlated with markers of
hepatic destruction (AST) and abnormal liver function
(c-glutamyl transpeptidase, alkaline phosphatase and
a-fetoprotein), and French et al. [39] showed that levels
of sCD14 were higher in HIV/HCV-coinfected women
during periods of liver disease progression than during
intervals when minimal or no progression occurred. We
did not find a relationship between sCD14 and any
indices of hepatocellular damage in this cohort, where
APRI scores are consistent with a low probability of
advanced liver damage. However, we found here that
plasma levels of two other markers of macrophage activa-
tion, sCD163 and neopterin, and levels of the IFN-induci-
ble protein IP-10 were significantly higher in HCV/HIV
coinfection than in HIV-infected patients not infected
with HCV and, while only sCD163 levels were correlated
with plasma levels of HCV, each was correlated with three
indices of hepatic damage (AST, ALT and APRI).
In earlier works, we and others found an inverse
relationship between indices of hepatocellular damage
and the frequency of circulating CD4 T-cell RTEs as
determined by the expression of CD31 [12,40]. In the
current work, we found that circulating levels of sCD163,
which are linked to indices of hepatocellular inflamma-
tion, were also correlated inversely with the numbers of
circulating na€ıve CD4 T cells and CD4 RTEs. The relation-
ship among these indices remains incompletely under-
stood but it is possible that processes taking place in the
liver may play a role in alteration of CD4 T-cell recovery
during ART in the setting of HCV/HIV coinfection.
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